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An important way in which medical research can translate into improved health outcomes is 
by motivating or influencing clinical trials that eventually lead to changes in clinical practice. 
Citations from clinical trials records to academic research may therefore serve as an early 
warning of the likely future influence of the cited articles. This paper partially assesses this 
hypothesis by testing whether prior articles referenced in ClinicalTrials.gov records are more 
highly cited than average for the publishing journal. The results from four high profile 
general medical journals support the hypothesis, although there may not be a cause-and 
effect relationship. Nevertheless, it is reasonable for researchers to use citations to their 
work from clinical trials records as partial evidence of the possible long-term impact of their 
research. 
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Introduction 
Medical research has the ultimate goal of improving health in society (e.g., 
http://www.mrc.ac.uk/about/) but it is rarely possible to demonstrate the direct benefits of 
individual studies due to the long gestation period before related treatments or 
interventions are approved for patients (e.g., Drolet, & Lorenzi, 2011; for a scientometric 
approach see: Jones & Hanney, 2016). Thus, it has become common to evaluate medical 
researchers both formally and informally with the aid of proxy indicators, such as the 
prestige or impact factors of the journals in which they publish, counts of citations to their 
articles, or their successful funding bids. A partial exception is the case study component of 
the UK Research Excellence Framework (REF) (http://impact.ref.ac.uk/CaseStudies/). The 
two citation based methods may undervalue research that is the most directly beneficial 
because health outcomes do not in themselves produce journal citations. Whilst basic 
research is important and can lead to long term social benefits (e.g., Smith, Mitchell, & 
McEwan, 2013), methods are needed to test for and, if necessary correct for, the apparent 
tendency for citation-based indicators to undervalue more applied medical research (e.g., 
Lewison & Dawson, 1998). One such indicator is the post-publication peer review scores 
given to biomedical articles by F1000 (Mohammadi & Thelwall, 2013). Moreover, citations 
can help to evaluate medical funders (Boyack & Jordan, 2011) and alternative metrics may 
help with this (Thelwall, Kousha, Dinsmore, & Dolby, 2016). Similar motivations have 
underpinned many attempts to develop altmetrics and other alternative indicators to reflect 
the different valid impacts generated by academics in many disciplines (Kousha & Thelwall, 
2015b; Thelwall & Delgado, 2015; Wilsdon, J. et al., 2015).  
The need for an indicator of the extent to which research informs health practice can 
be partially addressed by counting citations from medical guidelines (Drew, Pettibone, 
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Finch, Giles, & Jordan, 2016; Grant, Cottrell, Cluzeau, & Fawcett, 2000; Thelwall & Maflahi, 
2016; for patents, see: Chiou, Magazzini, Pammolli, & Riccaboni, 2016; Kousha & Thelwall, 
2015a). Nevertheless, it can take decades for medical research to translate into proven and 
safe health policies or medications and so citations from guidelines are unlikely to reflect 
recent research. Guideline citations may also tend to cite research that proves the efficacy 
or safety of a treatment rather than the primary research that invented the treatment or 
that initially demonstrated its promise. Citations from clinical trials records may fill both of 
these gaps by being substantially quicker and more likely to cite key innovations. There are 
now regulations mandating the public registration of clinical trials in some countries, such as 
the USA, where the responsible parties must register them in ClinicalTrials.gov prior to 
starting (Tse, Williams, & Zarin, 2009) and report results in a timely fashion (Prayle, Hurley, 
& Smyth, 2012). Moreover, some journals require published studies to have been pre-
registered in an appropriate site (Laine, Horton, DeAngelis, et al., 2007; Palma, & Zietman, 
2015). ClinicalTrials.gov contains information about a large number of public and 
commercial trials (Califf, Zarin, Kramer, Sherman, Aberle, & Tasneem, 2012; Hirsch, Califf, 
Cheng, et al., 2013; Ross, Mulvey, Hines, Nissen, & Krumholz, 2009; Stockmann, Sherwin, 
Koren, et al., 2014; Zarin, Tse, & Ide, 2005; Zarin, Tse, Williams, Califf, & Ide, 2011) and so it 
is now possible to count citations from clinical trials records. These citations can therefore 
be evaluated as a new source of evidence about the health benefits promise of medical 
research. Even though few trials based on published ideas lead to new treatments 
(Contopoulos-Ioannidis, Ntzani, & Ioannidis, 2003), the mere existence of a trial based on a 
publication suggests the potential practical value of the new ideas, if even fewer basic 
research findings lead to beneficial medical outcomes (e.g., Ioannidis, 2006). Nevertheless, 
the requirement for responsible parties to register clinical trials publicly is not 
internationally universal and there is no requirement to cite relevant prior work 
systematically. Hence, it is not clear whether there will be enough citations from clinical 
trials documents to be worth counting. It is also not clear whether citations from clinical 
trials are effectively random, biased or dominated by self-citations. 
This article introduces a method to count citations from clinical trials and assesses 
whether they are likely to be useful as impact evidence. In order to investigate the value of 
clinical trials citations, articles in four high profile general medical journals were compared 
based upon whether they had been referenced in ClinicalTrials.gov records. It is important 
to compare articles from the same journal because the prestige of a journal can affect the 
number of times that an article is cited (Larivière & Gingras, 2010) and journals have 
different disciplinary foci, leading to different natural citation rates for their articles (Seglen, 
1997). Selecting high profile journals ensures that the citation counts will tend to be high 
and the coverage of the journal will be large, both of which tend to maximise the statistical 
power of the analysis. The registry ClinicalTrials.gov was chosen despite the existence of 
many other registries internationally (Ogino, Takahashi, & Sato, 2014) due to its large 
downloadable collection of about 216,000 clinical studies from the United States and 193 
countries since 2000 (https://clinicaltrials.gov/ct2/resources/trends; 37% were US-only 
trials in May 2016). Although published clinical trials tend to be more highly cited than 
average for the publishing journal (Romero, Cortés, Escudero, López, & Moreno, 2009), it is 
not known whether the same is true for articles cited by clinical trial records. The following 
two questions are addressed. A positive answer to the first question would give evidence 
that citations from ClinicalTrials.org are not random and also that they could be used for 
impact indicators (van Raan, 1998), but would not demonstrate that they are unbiased or 
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unaffected by self-citations. This is therefore a first, but not final, step in validating clinical 
trials citation counts. 
 Do articles in The BMJ, the New England Journal of Medicine, The Lancet and JAMA 
tend to attract more citations than average for the publishing journals when they are 
referenced in ClinicalTrials.gov records? 
 How does the answer to the above question vary over time? 
Data and Methods 
Citations to journal articles in trials registered in ClinicalTrials.gov were identified by 
crawling all records in the site and extracting the cited references from the relevant sections 
of each document. The website permits crawling (https://www.clinicaltrials.gov/robots.txt) 
and makes comprehensive crawling without duplication possible with a crawler-friendly 
version of the site (https://www.clinicaltrials.gov/ct2/crawl). This was crawled by the free 
web crawler SocSciBot (socscibot.wlv.ac.uk) during April 19-24, 2016. A program was 
written to extract the cited publications (and other information) from each record. This is 
available in the free software Webometric Analyst (lexiurl.wlv.ac.uk: the ClinicalTrials.gov 
options in the Services and Citations menus).  
Citations in trial records can be entered by the uploader or automatically inserted by 
ClinicalTrials.gov from trials that cite the study by its reference number. The automatically 
added citations are unlikely to have influenced the trials since they must have been 
published after the trial was registered in the site and hence all such citations were 
removed. In addition, the remaining citations are at the discretion of the uploader and may 
also refer to articles that publish the trial results, are influenced by the trial, or are 
otherwise related to the trial without influencing it. To reduce the possibility of these 
happening, only articles that had been published at least a year before the study start date 
were retained. Given normal publishing delays, these articles are likely to refer to research 
that was conducted at least 1-2 years prior to the start of the study and seem unlikely to be 
about the study rather than influencing it. This is a conservative approach given that articles 
publishing clinical trials results tend to appear about two years after the trial data collection 
has finished (Riveros, Dechartres, Perrodeau, Haneef, Boutron, & Ravaud, 2013). 
The citation counts of all regular articles in the four journals were extracted from 
Scopus using queries for the journal ISSN, the document type article, and each year from 
2008 to 2016. Multiple ISSNs for a journal in Scopus (e.g., electronic and print) were 
searched separately. For example, one JAMA query was: 
ISSN(1538-3598) AND DOCTYPE(ar) AND PUBYEAR IS 2015 
The range 2008 to 2016 was chosen because 2008 was the first year in which the journal 
articles (almost) all had DOIs in Scopus. 
Articles mentioned in ClinicalTrials.gov records can be referenced in many different 
formats and with many different variants of journal names. To ensure that articles 
referenced in trials records were correctly matched to their Scopus record, the matching 
process used article DOIs, when present. The remaining articles were matched by journal 
name (standardised across common variants), publication year and title (converted to lower 
case). Most articles contained DOIs and so this was the dominant matching mechanism. 
Articles referenced in trials that were not matched to a Scopus record despite having been 
published in one of the journals and years covered were ignored. These were predominantly 
non-article types of document (e.g., editorials, errata, images, comments, letters). 
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 For each year, the average citation counts of articles referenced in ClinicalTrials.gov 
were compared against the average citation counts of the remaining articles in the four 
journals examined. Individual years were analysed separately because older articles can be 
expected to have higher citation counts. Articles published early in the year have longer to 
be cited compared to articles published later in the year but this advantage seems unlikely 
to affect either of the two groups more than the other and so this factor was ignored. 
Although there is a statistical technique to deal with this issue, it does not allow effect sizes 
to be estimated (Thelwall, Haustein, Larivière, & Sugimoto, 2013) and so it was not used. For 
each journal/year combination, citation averages were calculated using the geometric mean 
with a 1 offset because citation data is highly skewed and so the arithmetic mean is 
inappropriate (Fairclough & Thelwall, 2015; Zitt, 2012). All citation counts were normalised 
by dividing by the geometric mean citation count for the journal and year of publication. 
This is an extension of the standard citation normalisation technique (Waltman, van Eck, van 
Leeuwen, Visser, & van Raan, 2011ab). This also allows 95% confidence intervals to be 
calculated for the (geometric) mean using the normal distribution formula both within 
individual years and across years. 
Results 
In each of the four journals, the average number of citations attracted by prior articles 
referenced in ClinicalTrials.gov records is substantially higher than the average number of 
citations attracted by other articles in the same journals (Table 1). This supports the 
hypothesis that citation by a clinical trial record is evidence of the likelihood of an article 
having above average impact, at least for its publishing journal (RQ1). 
 
Table 1. Journal and year geometric mean normalised citation counts for prior articles 
referenced in ClinicalTrials.gov and other articles in the four journals (geometric mean, 95% 
confidence interval and sample size). 
Journal 
Mean citation count 
of articles referenced 
in ClinicalTrials.gov 
Mean citation count 
of articles not 
referenced in 
ClinicalTrials.gov 
BMJ 
8.5 (7.1, 10.2) 
N=123 
1.4 (1.3, 1.5) 
N=3937 
JAMA 
3.5 (3.1, 4.0) 
N=212 
1.3 (1.2, 1.4) 
N=1681 
The Lancet 
8.1 (7.1, 9.3) 
N=291 
1.3 (1.3,1.4) 
N=2817 
NEJM 
12.1 (11.2, 13.1) 
N=489 
1.5 (1.5, 1.7) 
N=3025 
 
The temporal trend in results varies by publishing journal (Figs. 1-4; see Table 2 for sample 
sizes). The BMJ and JAMA results are broadly consistent with no changes over time, whereas 
the results from The Lancet suggest lower evidence of impact for more recently published 
articles and the NEJM results are consistent with both. The current year (2016) is missing 
from the graphs because no trial recording a future start date (2017 or later) cited articles 
from any of the four journals published in 2016. Overall, then, the data does not give strong 
evidence of a substantial time lag between being referenced in a clinical trials record and 
becoming highly cited (RQ2). 
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Because all citation counts are normalised by dividing by the journal geometric 
mean, only the relative size difference between the two sets is important. For example, the 
graphs mask (as irrelevant for this paper) the fact that NEJM is more highly cited than The 
BMJ. 
 
Table 2. The number of articles in each of the four journals analysed that were referenced 
or not referenced by ClinicalTrials.gov records. 
Publication 
year 
BMJ 
cited 
BMJ 
uncited 
Jama 
cited 
Jama 
uncited 
Lancet 
cited 
Lancet 
uncited 
NEJM 
cited 
NEJM 
uncited 
2008 8 430 44 154 37 581 71 370 
2009 25 350 51 171 25 572 64 394 
2010 31 339 42 176 18 431 61 375 
2011 22 326 35 174 18 279 60 365 
2012 28 494 38 211 10 252 52 398 
2013 15 577 41 213 6 241 39 392 
2014 14 661 37 225 4 232 24 389 
2015 5 624 26 196 2 304 22 350 
2016 1 110 4 55 2 94 8 80 
All 149 3911 318 1575 122 2986 401 3113 
 
 
 
 
Figure 1. Journal and year normalised average numbers of citations for articles published 
between 2008 and 2016 in The BMJ: articles referenced in ClinicalTrials.gov records (and 
published before the study start date) against the remaining articles. 
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Figure 2. As above for The Lancet. 
 
 
Figure 3. As above for JAMA. 
 
 
Figure 4. As above for NEJM. 
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Discussion and conclusions 
An important limitation is that ClinicalTrials.gov is a US-based site and therefore its citations 
can be expected to have a bias towards the US, as is the case with journal citations (Lancho-
Barrantes, Bote, Vicente, Rodríguez, & de Moya Anegón, 2012). The methodological 
restriction to a small number of high impact journals is another important limitation 
because these account for a small minority of medical articles and it is not clear that the 
patterns found in them would extend to the generality of medical research. For example, a 
high proportion of publications in high impact journals about a new topic is a statistically 
significant indirect indicator of a drug eventually being marketed (Kissin, 2010).  Another 
weak point is that citation counts do not seem to reflect the quality of clinical trials (Akcan, 
Axelsson, Bergh, Davidson, & Rosén, 2013) and so citation-based metrics may not be useful 
indicators for trial-related publications. Finally, citations from clinical trials records may be 
biased in some way, may have a high proportion of self-citations, may disproportionately 
cite high impact types of documents (e.g., randomized control trials, systematic reviews or 
meta analyses) rather than primary research. Moreover, papers may also be more 
referenced by clinical trials if they have many authors or more funding, which may also 
affect their Scopus citation counts (e.g., Glänzel & Schubert, 2001). Thus, a more detailed 
analysis of the individual citations would be needed to validate the use of clinical trials 
citations for evaluation purposes. 
 The results give strong statistical evidence that articles from four leading medical 
journals that are cited with DOIs in ClinicalTrials.gov have higher citation counts than typical 
articles from the journal, at least for those that are 2-6 years old, depending on the journal, 
with the difference probably being due to statistical power differences rather than journal 
differences. There are at least four potential reasons for the higher citation impact found.  
 Articles referenced in ClinicalTrials.gov lead to medical or health care innovations by 
motivating (at least in part) the trials, and this value leads to them being more 
recognised and cited (including in articles derived from the trials). 
 Articles referenced in ClinicalTrials.gov do not lead to medical or health care 
innovations but become more cited due to (a) being cited in articles derived from 
unsuccessful trials and/or (b) publicity due to the presence of the citation in the trial 
reference list. 
 Articles referenced in ClinicalTrials.gov are disproportionately often self-citations 
from the clinical trials scientists, who tend to be highly cited successful researchers 
because they attract funding for clinical trials. 
 Older articles referenced in ClinicalTrials.gov are selected because of their high 
citation counts, either directly (as prestigious articles) or indirectly (due to ranking 
boosts in digital library search engines or because their high contribution to research 
has already been recognised and led to high citations). 
 Articles referenced in ClinicalTrials.gov tend to be highly cited types of articles, such 
as randomised control trials, systematic reviews or meta-analyses. 
Citation in ClinicalTrials.gov would be most useful as an alternative impact indicator in the 
first case only because in the third and fourth cases, the indicator would tend to confirm 
what other indicators would show and in the second case the citation does not reflect a 
valuable contribution of the cited research. The higher citation impact is in addition to the 
more direct impact that articles can have on health outcomes through supporting or 
motivating clinical trials. 
8 
 
 The temporal results were inconclusive but do not give strong evidence for the value 
of using citation in a clinical trial record as evidence of likely future higher citation impact. 
Logically, however, the opposite is almost certainly true. Although articles published in the 
same year as the start of a trial were excluded for methodological reasons, when they are 
not derived from a trial then it would be valid to count contemporary trial citations to them. 
Thus, it would be possible to use citations from trials in the current year as evidence of likely 
future impact in practice. Such articles would be likely to have low numbers of journal 
article citations due to their newness and so the trial citation would be a valuable impact 
indicator. 
A practical application of the findings is that researchers can use the presence of 
citations to their work in clinical trials records to support a claim for its potential long-term 
impact. Such citations can be found easily by searching the site using their last name (e.g., 
Google site:clinicaltrials.gov/ct2/show/ Whooley) or the titles of their articles (e.g., Google 
site:clinicaltrials.gov/ct2/show/ “Prevalence of symptomatic pelvic floor disorders in US 
women”), and manually checking for correct matches. Given the possibility of irrelevant 
citations, as discussed above, authors might accompany such claims by brief contextual 
justification of the value of the cited research to the study (e.g., “informed study methods”). 
From a wider research policy perspective, the potential of researchers to use evidence of 
citations from clinical trials as an indicator of likely future impact may provide a mild 
incentive to them to encourage the translation of their ideas into practice, which would 
presumably be a public good. 
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Appendix: Specific method details 
The free web crawler SocSciBot (http://socscibot.wlv.ac.uk) crawled the ClinicalTrials.gov 
index site at https://www.clinicaltrials.gov/ct2/crawl) and the link files in the SocSciBot link 
results folder imported into Excel and used to extract a complete list of URLs. From these 
URLs, a complete list of standard study URLs was generated. 
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A second SocSciBot crawl was then started, using a 1-second pause between 
requests (for politeness) and using a dummy fake startup URL and the above list of URLs as 
the start.txt initial list (this ensures that only URLs in the list are crawled). 
When the crawl had finished, the free Webometric Analyst software 
(http://lexiurl.wlv.ac.uk) was used to extract the relevant information as follows. 
 The Services menu, ClinicalTrials.gov: Extract information from SocSciBot crawl (e.g., 
AgesEligible, MeshTerms, Publications, PubsLinkedViaNCT) menu item was used to 
extract relevant information from the crawled pages (pointing the program to the 
root folder for the second crawl). >> Record list file. 
 The Services menu, ClinicalTrials.gov: Summarise results of the above (e.g., study 
type, gender by year: pubs; keyword freqs.) menu item was used to generate 
summary information (pointing the program to the record list file generated above). 
>> Summary tables files. 
 The Citation menu, Clinicaltrials.gov (or similar): Extract citations from |-separated 
col, extract doi and year, match with record year menu item was used to generate 
lists of users-added publications (pointing the program to the record list file 
generated above, and selecting the user-added publications column). >> List of user 
added publications file. 
 Using Scopus, a list of all publications of type journal article was extracted for JAMA, 
BMJ, Lancet and NEJM. >> Scopus journal file. 
 The Scopus publication list was matched with each of the above two publications 
files by exact doi matching (case insensitive) or, for articles without DOI matches, 
title, journal name and year matching (case insensitive) using the Citation menu,  
Match DOIs or article title, year, journal from one file with same info from another 
menu item (selecting the Scopus journal file first, then the List of user added 
publications file). >> List of user added publications and matching Scopus records 
file. 
 Duplicate user added publication matches (i.e., the same publication cited by 
different trials records) were removed in Excel. Publications from the same or later 
year than the trial start year were also removed in Excel. >> List of unique user 
added prior publications and matching Scopus records file.  
 Geometric mean normalised citation counts for each file were created using the 
Citation menu,  Calculate geometric mean normalised citation counts for a marked 
subset of articles, separately by year menu item (selecting the Scopus journal file 
first, then the List of user added publications file). >>geometric mean normalised 
user added results file. 
 
